FDA's Cardiovascular and Renal Drugs Advisory Committee will review nesiritide May 25 for treatment of acute congestive heart failure. Scios resubmitted an amended NDA for the product Jan. 10. FDA had issued a "non-approvable" letter and requested further trial information in April 199
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
